Pajjiż: Stati Uniti
Lingwa: Ingliż
Sors: NLM (National Library of Medicine)
CELECOXIB (UNII: JCX84Q7J1L) (CELECOXIB - UNII:JCX84Q7J1L)
REMEDYREPACK INC.
ORAL
PRESCRIPTION DRUG
Celecoxib capsules are indicated For the management of the signs and symptoms of OA [ see Clinical Studies ( 14.1) ] For the management of the signs and symptoms of RA [ see Clinical Studies ( 14.2) ] For the management of the signs and symptoms of JRA in patients 2 years and older [ see Clinical Studies ( 14.3) ] For the management of the signs and symptoms of AS [ see Clinical Studies ( 14.4) ] For the management of acute pain in adults [ see Clinical Studies ( 14.5) ] For the management of primary dysmenorrhea [ see Clinical Studies ( 14.5) ] • Celecoxib capsules are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug produc
Celecoxib Capsules 50 mg Size '4', White opaque cap, white opaque body with 'C4' imprinted on the red band on the cap and '50mg' imprinted on the red band on the body and are available as follows: Bottles of 60 Capsules NDC 33342-155-09 Celecoxib Capsules 100 mg Size '4', White opaque cap, white opaque body with 'C5' imprinted on the blue band on the cap and '100mg' imprinted on the blue band on the body and are available as follows: Bottles of 100 Capsules NDC 33342-156-11 Bottles of 500 Capsules NDC 33342-156-15 Unit dose blister pack of 100 Capsules NDC 33342-156-12 Celecoxib Capsules 200 mg Size '2', White opaque cap, white opaque body with 'C6' imprinted on the yellow band on the cap and '200mg' imprinted on the yellow band on the body and are available as follows: Bottles of 100 Capsules NDC 33342-157-11 Bottles of 500 Capsules NDC 33342-157-15 Unit dose blister pack of 100 Capsules NDC 33342-157-12 Celecoxib Capsules 400 mg Size '0 elongated', White opaque cap, white opaque body with 'C7' imprinted on the green band on the cap and '400mg' imprinted on the green band on the body and are available as follows: Bottles of 60 Capsules NDC 33342-158-09 Unit dose blister pack of 100 Capsules NDC 33342-158-12 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Abbreviated New Drug Application
CELECOXIB- CELECOXIB CAPSULE REMEDYREPACK INC. ---------- . Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) What is the most important information I should know about medicines called Nonsteroidal Anti- inflammatory Drugs (NSAIDs)? NSAIDs can cause serious side effects, including: • Increased risk of a heart attack or stroke that can lead to death. This risk may happen early in treatment and may increase: o with increasing doses of NSAIDs o with longer use of NSAIDs Do not take NSAIDs right before or after a heart surgery called a “coronary artery bypass graft (CABG)." Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. • Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines: o anytime during use o without warning symptoms o that may cause death •The risk of getting an ulcer or bleeding increases with: o past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs o taking medicines called “corticosteroids”, “antiplatelet drugs”, “anticoagulants”, “SSRIs” or “SNRIs” o increasing doses of NSAIDs o older age o longer use of NSAIDs o poor health o smoking o advanced liver disease o drinking alcohol o bleeding problems •NSAIDs should only be used: o exactly as prescribed o at the lowest dose possible for your treatment o for the shortest time needed What are NSAIDs? NSAIDs are used to treat pain and redness, swelling, and heat (inflammation) from medical conditions such as different types of arthritis, menstrual cramps, and other types of short-term pain. Who should not take NSAIDs? Do not take NSAIDs: • if you have had an asthma attack, hives, or other allergic reaction with aspirin or any other NSAIDs. • right before or after heart bypass surgery. Before taking NSAIDS, tell your healthcare provider about a Aqra d-dokument sħiħ
CELECOXIB- CELECOXIB CAPSULE REMEDYREPACK INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE CELECOXIB CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR CELECOXIB CAPSULES. CELECOXIB CAPSULES, FOR ORAL USE INITIAL U.S. APPROVAL: 1998 WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING. _ • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) CAUSE AN INCREASED RISK OF SERIOUS CARDIOVASCULAR THROMBOTIC EVENTS, INCLUDING MYOCARDIAL INFARCTION AND STROKE, WHICH CAN BE FATAL. THIS RISK MAY OCCUR EARLY IN THE TREATMENT AND MAY INCREASE WITH DURATION OF USE. ( 5.1) • CELECOXIB CAPSULES ARE CONTRAINDICATED IN THE SETTING OF CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY. ( 4, 5.1) • NSAIDS CAUSE AN INCREASED RISK OF SERIOUS GASTROINTESTINAL (GI) ADVERSE EVENTS INCLUDING BLEEDING, ULCERATION, AND PERFORATION OF THE STOMACH OR INTESTINES, WHICH CAN BE FATAL. THESE EVENTS CAN OCCUR AT ANY TIME DURING USE AND WITHOUT WARNING SYMPTOMS. ELDERLY PATIENTS AND PATIENTS WITH A PRIOR HISTORY OF PEPTIC ULCER DISEASE AND/OR GI BLEEDING ARE AT GREATER RISK FOR SERIOUS GI EVENTS. ( 5.2) RECENT MAJOR CHANGES Warnings and Precautions, ( 5.1, 5.4) 6/2018 Warnings and Precautions ( 5.2) 5/2019 INDICATIONS AND USAGE Celecoxib capsules are a nonsteroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) ( 1.1) • Rheumatoid Arthritis (RA) ( 1.2) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older ( 1.3) • Ankylosing Spondylitis (AS) ( 1.4) • Acute Pain (AP) ( 1.5) • Primary Dysmenorrhea (PD) ( 1.6) DOSAGE AND ADMINISTRATION • Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals ( 2.1) • OA: 200 mg once daily or 100 mg twice daily ( 2.2, 14.1) • RA: 100 mg to 200 mg twice daily ( 2.3, 14.2) • JRA: 50 mg twice daily in patients 10 kg to 25 kg. 100 mg twice daily in patients more than 25 k Aqra d-dokument sħiħ